R. Pierre-simon and M. , PhD Service d'Hématologie Clinique et Service d'Onco-Hématologie Pédiatrique

F. Frassoni, A. Barrett, A. Granena, P. Ernst, G. Garthon et al., Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases, British Journal of Haematology, vol.1, issue.3, pp.317-320, 1988.
DOI : 10.2307/2281868

J. Mortimer, M. Blinder, S. Schulman, S. Schulman, F. Appelbaum et al., Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy., Journal of Clinical Oncology, vol.7, issue.1, pp.50-57, 1989.
DOI : 10.1200/JCO.1989.7.1.50

J. Radich, J. Sanders, C. Buckner, P. Martin, F. Petersen et al., Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens., Journal of Clinical Oncology, vol.11, issue.2, pp.304-313, 1993.
DOI : 10.1200/JCO.1993.11.2.304

A. Barrett, F. Locatelli, J. Treleaven, A. Gratwohl, R. Szyd?o et al., Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY, British Journal of Haematology, vol.7, issue.4, pp.567-574, 1991.
DOI : 10.2307/2281868

M. Michallet, M. Tanguy, G. Socie, A. Thiébaut, A. Belhabri et al., Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM), British Journal of Haematology, vol.300, issue.2, pp.400-407, 2000.
DOI : 10.1038/sj.bmt.1700720

M. Eapen, S. Giralt, M. Horowitz, J. Klein, J. Wagner et al., Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant, Bone Marrow Transplantation, vol.34, issue.8, pp.721-727, 2004.
DOI : 10.1038/sj.bmt.1704645

A. Bosi, D. Laszlo, M. Labopin, J. Reffeirs, M. Michallet et al., Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation, Journal of Clinical Oncology, vol.19, issue.16, pp.3675-3684, 2001.
DOI : 10.1200/JCO.2001.19.16.3675

C. Hosing, R. Saliba, M. Shahjahan, E. Estey, D. Couriel et al., Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia, Bone Marrow Transplantation, vol.18, issue.2, pp.157-162, 2005.
DOI : 10.1038/sj.bmt.1701146

H. Kolb, A. Schattenberg, J. Goldman, B. Hertenstein, N. Jacobsen et al., Graftversus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients

D. Porter, M. Roth, S. Lee, C. Mcgarigle, J. Ferrara et al., Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation, Bone Marrow Transplant, vol.18, pp.975-980, 1996.

R. Collins, . Jr, O. Shpilberg, W. Drobyski, D. Porter et al., Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation., Journal of Clinical Oncology, vol.15, issue.2, pp.433-444, 1997.
DOI : 10.1200/JCO.1997.15.2.433

J. Levine, T. Braun, S. Penza, P. Beatty, K. Cornetta et al., Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation, Journal of Clinical Oncology, vol.20, issue.2, pp.405-412, 2002.
DOI : 10.1200/JCO.2002.20.2.405

C. Schmid, M. Labopin, A. Nagler, M. Bornhäuser, J. Finke et al., Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party, Journal of Clinical Oncology, vol.25, issue.31, pp.4938-4983, 2007.
DOI : 10.1200/JCO.2007.11.6053

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-81, 1958.
DOI : 10.1214/aoms/1177731566

D. Rubin, Multiple Imputation for Nonresponse in Surveys, 1987.
DOI : 10.1002/9780470316696

V. Stackelberg, A. Völzke, E. Kühl, J. Seeger, K. Schrauder et al., Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group, European Journal of Cancer, vol.47, issue.1
DOI : 10.1016/j.ejca.2010.09.020

P. Bader, H. Kreyenberg, G. Henze, C. Eckert, M. Reising et al., Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group, Journal of Clinical Oncology, vol.27, issue.3, pp.377-84, 2009.
DOI : 10.1200/JCO.2008.17.6065

V. Van-der-velden, A. Van-der-sluijs-geling, B. Gibson, J. Te-marvelde, P. Hoogeveen et al., Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol, Leukemia, vol.110, issue.9, pp.1599-606, 2010.
DOI : 10.1038/leu.2010.153

G. Reaman and F. Smith, Childhood leukemia, 2011.
DOI : 10.1007/978-3-642-13781-5

J. Rubnitz and H. Inaba, Childhood acute myeloid leukaemia, British Journal of Haematology, vol.148, issue.3, pp.259-76, 2012.
DOI : 10.1111/bjh.12040

G. Zugmaier, N. Gökbuget, M. Klinger, R. Bargou, and M. Topp, Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment, Blood, vol.126, issue.24, pp.2578-84, 2015.
DOI : 10.1182/blood-2015-06-649111

P. Schlegel, P. Lang, G. Zugmaier, T. Feuchtinger, and R. Handgretinger, Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab, Haematologica, vol.99, issue.7
DOI : 10.3324/haematol.2013.100073

T. Zhang, L. Cao, J. Xie, H. Chen, and Y. Zhang, Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis, Oncotarget, vol.6, issue.32, pp.33961-71, 2015.

S. Van-der-stegen, M. Hamieh, and M. Sadelain, The pharmacology of second-generation chimeric antigen receptors, Nature Reviews Drug Discovery, vol.366, issue.7, pp.499-509, 2015.
DOI : 10.1038/nrd4597